Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study
Conclusion: NOACs had better long-term risk-benefit profiles than VKAs. While effectiveness was comparable, apixaban was overall associated with a more favorable safety profile followed by dabigatran.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Atrial Fibrillation | Belgium Health | Bleeding | Diabetes | Drugs & Pharmacology | Endocrinology | Gastroenterology | Heart Attack | Hemorrhagic Stroke | Pradaxa | Stroke | Study | Vitamin K | Vitamins